Sarat Chandarlapaty
@saratchandarlapaty.bsky.social
Physician Scientist, Medical Oncologist, My lab studies therapy resistance in breast cancer.
Reposted by Sarat Chandarlapaty
ADC resistance is likely heterogeneous, and the phenomena above may explain only a portion of cases. But these early clues can inform prospective trail efforts, as well as ADC sequencing strategies. There is much more to come!
November 10, 2025 at 4:55 PM
ADC resistance is likely heterogeneous, and the phenomena above may explain only a portion of cases. But these early clues can inform prospective trail efforts, as well as ADC sequencing strategies. There is much more to come!
Reposted by Sarat Chandarlapaty
A hugely collaborative team effort under the mentorship of @saratchandarlapaty.bsky.social @mskcancercenter.bsky.social
December 13, 2024 at 1:14 AM
A hugely collaborative team effort under the mentorship of @saratchandarlapaty.bsky.social @mskcancercenter.bsky.social